Interleukin 13, Recombinant, Mouse (IL-13)

Source: \nRecombinant corresponding to mouse IL-13 expressed in E. coli.\n\nMolecular Weight: \n~12kD\n\nActivity:\nED50 range =2-6ng/ml, determined by the dose dependent proliferation of TF-1 cells. The optimal concentration for each specific application should be determined by an initial dose response assay.\n\nEndotoxin: ~0.1ng/ug\n\nStorage and Stability:\nLyophilized powder may be stored at -20 degrees C. Stable for 12 months at -20 degrees C. Reconstitute with sterile ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

I8435-11A

Size

10ug

Form

Supplied as a lyophilized powder. BSA free. Reconstitute with sterile ddH2O to 0.1-1mg/ml.

Purity

~98% (SDS-PAGE)

References

1. Brown, K.D., S.M. Zurawski, T.R. Mosman, and G. Zurawski (1989) A family of small inducible proteins secreted by leukocytes are members of a new superfamily that includes leukocyte and fibroblast-derived inflammatory agents, growth factors, and indicators of various activation processes. J. Immunol. 142:679-687. 2. McKenzie, A.N., and G. Zurawski (1995) Interleukin 13: characterization and biologic properties. Cancer Treat. Res. 80:367-378. 3. Malabarba, M.G., H. Rui, H.H. Deutsch, J. Chung, F.S. Kalthoff, W.L. Farrar, and R.A. Kirken (1996) Interleukin 13 is a potent activator of JAK3 and STAT6 in cells expressing interluekin-2 receptor-gamma and interleukin-4 receptor-alpha. Biochem. J. 319:865-872. 4. Muchamuel, T., S. Menon, P. Pisacane, M.C. Howard, and D.A. Cockayne (1997) IL-13 protects mice from lipopolysaccharide-induced lethal endotoxemia: correlation with down-modulation of TNF-alpha, IFN-gamma, and IL-12 production. J. Immunol. 158:2898-2903. 5. Wills-Karp, M., J. Luyimbazi, X. Xu, B. Schofield, T.Y. Neben, C.L. Karp, and D.D. Donaldson (1998) Interleukin-13: central mediator of allergic asthma. Science 282:2258-2261. 6. Chang, C.I., B. Zoghi, J.C. Liao, and L. Kuo (2000) The involvement of tyrosine kinases, cyclic AMP/protein kinase A, and p38 mitogen-activated protein kinase in IL-13-mediated arginase I induction in macrophages: its implications in IL-13 inhibited nitric oxide production. J. Immunol. 165:2134-2141. 7. Jones, M., M. Komatsu, and R.B. Levy (2000) Cytotoxically impaired transplant recipients can efficiently resist major histocompatibility complex-matched bone marrow allografts. Biol. Blood Marrow Transplantation 6(4A):456-464. 8. Pope, S.M., E.B. Brandt, A. Mishra, S.P. Hogan, N. Zimmermann, K.I. Matthaei, P.S. Foster, and M.E. Rothenberg (2001) IL-13 induces eosinophil recruitment into the lung by an IL-5-and eotaxin-dependent mechanism. J. Allergy Clin. Immunol. 108:594-601. 9. Yang, M., S.P. Hogan, P.J. Henry, K.I. Matthaei, A.N. McKenzie, I.G. Yound, M.E. Rothenberg, and P.S. Foster (2001) Interleukin-13 mediates airways hyperreactivity through the IL-4 receptor-alpha chain and STAT-6 independently of IL-5 and eotaxin. Am. J. Respir. Cell Mol. Biol. 25:522-530.